Your browser doesn't support javascript.
loading
Efficiency of nilotinib to target chronic phase-chronic myeloid leukaemia primary mature CD34- and immature CD34+ cells.
Berger, Marc G; Lebecque, Benjamin; Tassin, Thomas; Dannus, Louis-Thomas; Berger, Juliette; Soucal, Mélanie; Guerci, Agnès; Cony-Makhoul, Pascale; Johnson, Hyacinthe; Etienne, Gabriel; Guyotat, Denis; Gagnieu, Marie-Claude; Pereira, Bruno; Saugues, Sandrine; Tournilhac, Olivier; Hermet, Eric; Bourgne, Céline.
Affiliation
  • Berger MG; Hématologie Biologique, CHU Clermont-Ferrand, Hôpital Estaing, 1 place Lucie et Raymond Aubrac, 63003, Clermont-Ferrand Cedex 1, France.
  • Lebecque B; Equipe d'Accueil 7453 CHELTER, Université Clermont Auvergne, CHU Clermont-Ferrand, Hôpital Estaing, 1 place Lucie et Raymond Aubrac, 63003, Clermont-Ferrand Cedex 1, France.
  • Tassin T; CRB-Auvergne, CHU Clermont-Ferrand, Hôpital Estaing, 1 place Lucie et Raymond Aubrac, 63003, Clermont-Ferrand Cedex 1, France.
  • Dannus LT; Hématologie Clinique, CHU Clermont-Ferrand, Hôpital Estaing, 1 place Lucie et Raymond Aubrac, 63003, Clermont-Ferrand, France.
  • Berger J; Hématologie Biologique, CHU Clermont-Ferrand, Hôpital Estaing, 1 place Lucie et Raymond Aubrac, 63003, Clermont-Ferrand Cedex 1, France.
  • Soucal M; Equipe d'Accueil 7453 CHELTER, Université Clermont Auvergne, CHU Clermont-Ferrand, Hôpital Estaing, 1 place Lucie et Raymond Aubrac, 63003, Clermont-Ferrand Cedex 1, France.
  • Guerci A; Hématologie Biologique, CHU Clermont-Ferrand, Hôpital Estaing, 1 place Lucie et Raymond Aubrac, 63003, Clermont-Ferrand Cedex 1, France.
  • Cony-Makhoul P; Equipe d'Accueil 7453 CHELTER, Université Clermont Auvergne, CHU Clermont-Ferrand, Hôpital Estaing, 1 place Lucie et Raymond Aubrac, 63003, Clermont-Ferrand Cedex 1, France.
  • Johnson H; Hématologie Biologique, CHU Clermont-Ferrand, Hôpital Estaing, 1 place Lucie et Raymond Aubrac, 63003, Clermont-Ferrand Cedex 1, France.
  • Etienne G; Equipe d'Accueil 7453 CHELTER, Université Clermont Auvergne, CHU Clermont-Ferrand, Hôpital Estaing, 1 place Lucie et Raymond Aubrac, 63003, Clermont-Ferrand Cedex 1, France.
  • Guyotat D; Hématologie Biologique, CHU Clermont-Ferrand, Hôpital Estaing, 1 place Lucie et Raymond Aubrac, 63003, Clermont-Ferrand Cedex 1, France.
  • Gagnieu MC; Equipe d'Accueil 7453 CHELTER, Université Clermont Auvergne, CHU Clermont-Ferrand, Hôpital Estaing, 1 place Lucie et Raymond Aubrac, 63003, Clermont-Ferrand Cedex 1, France.
  • Pereira B; CRB-Auvergne, CHU Clermont-Ferrand, Hôpital Estaing, 1 place Lucie et Raymond Aubrac, 63003, Clermont-Ferrand Cedex 1, France.
  • Saugues S; Hématologie Biologique, CHU Clermont-Ferrand, Hôpital Estaing, 1 place Lucie et Raymond Aubrac, 63003, Clermont-Ferrand Cedex 1, France.
  • Tournilhac O; Equipe d'Accueil 7453 CHELTER, Université Clermont Auvergne, CHU Clermont-Ferrand, Hôpital Estaing, 1 place Lucie et Raymond Aubrac, 63003, Clermont-Ferrand Cedex 1, France.
  • Hermet E; Hématologie Clinique, CHU Nancy, Hôpitaux de Brabois, Rue du Morvan, 54500, Vandoeuvre-lès-Nancy, France.
  • Bourgne C; Hématologie Clinique, CH Annecy-Genevois, 1 Avenue de l'Hôpital, 74370, Metz-Tessy, France.
Sci Rep ; 11(1): 6187, 2021 03 17.
Article in En | MEDLINE | ID: mdl-33731863
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Leukemia, Myeloid, Chronic-Phase / Apoptosis / Drug Resistance, Neoplasm / Antigens, CD34 Type of study: Prognostic_studies Limits: Humans Language: En Journal: Sci Rep Year: 2021 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Leukemia, Myeloid, Chronic-Phase / Apoptosis / Drug Resistance, Neoplasm / Antigens, CD34 Type of study: Prognostic_studies Limits: Humans Language: En Journal: Sci Rep Year: 2021 Document type: Article Affiliation country: Country of publication: